Italia markets closed

Sanofi (SAN.PA)

Paris - Paris Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
85,78+0,32 (+0,37%)
Alla chiusura: 05:39PM CET
Schermo intero
Chiusura precedente85,46
Aperto86,15
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno85,29 - 86,48
Intervallo di 52 settimane80,60 - 105,18
Volume1.286.317
Media Volume1.641.763
Capitalizzazione107,559B
Beta (5 anni mensile)0,46
Rapporto PE (ttm)11,88
EPS (ttm)7,22
Prossima data utili01 feb 2024
Rendimento e dividendo (futuro)3,56 (4,17%)
Data ex dividendo30 mag 2023
Stima target 1A100,70
  • GlobeNewswire

    Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis

    Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis Patients treated with amlitelimab experienced up to 61.5% improvement in average Eczema Area and Severity Index (EASI) score from baseline at week 16, the primary endpoint, with continued improvement seen through 24 weeksClinically meaningful improvements were seen in all key secondary endpoints at week 16 with continued improvements through week 24, including for IGA 0/1 where pat

  • GlobeNewswire

    Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

    Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment TEV’574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s diseaseCollaboration supports Sanofi’s immunology strategy of exploring novel mechanisms of action for chronic inflammatory diseasesCollaboration leverages the innovative R&D and commercial expertise of both companies Paris, France and Parsippany, New Jersey, October 4, 2023. Sanofi (EURONEXT: SAN and NASDA

  • GlobeNewswire

    Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

    Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive ExPEC disease (IED) annually, worldwide1,2Phase 3 clinical trial of vaccine candidate ongoing. Novel ExPEC vaccine expected to complement existing older adult vaccine portfolio Paris, October 3, 2023. Sanofi announces today that it has entered into an agreeme